Home › Funds › BVF INC/IL › MLTX
BVF INC/IL position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
BVF INC/IL reported holding 16,001,284 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$311.5M, representing 7.97% of its reported portfolio and ranking #4 among its reported holdings. BVF INC/IL has disclosed MLTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BVF INC/IL's MLTX position evolved
BVF INC/IL first disclosed a stake in MLTX in Q3 2023 at 21,751,284 shares (US$1.24B). The position peaked in Q4 2023 at 21,751,284 shares, worth US$1.31B. Across 12 filings, BVF INC/IL increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 16,001,284 shares valued at US$311.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 21.75M | $1.24B | New |
| Q4 2023 | 21.75M | $1.31B | Hold |
| Q1 2024 | 21.75M | $1.09B | Hold |
| Q2 2024 | 21.75M | $956.40M | Hold |
| Q3 2024 | 21.75M | $1.10B | Hold |
| Q4 2024 | 19.75M | $1.07B | Reduce |
| Q1 2025 | 19.75M | $771.68M | Hold |
| Q2 2025 | 19.75M | $932.26M | Hold |
| Q3 2025 | 19.75M | $141.62M | Hold |
| Q4 2025 | 19.75M | $260.32M | Hold |
| Q1 2026 | 16.00M | $298.26M | Reduce |
| Q2 2026 | 16.00M | $311.54M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 29 other funds we track also report a position in MLTX — the largest reported positions include Deep Track Capital, LP (US$136.3M), Cormorant Asset Management, LP (US$62.4M), Logos Global Management LP (US$52.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- Deep Track Capital, LP 7.00M sh · $136.27M · Q2 2026
- Cormorant Asset Management, LP 3.21M sh · $62.41M · Q2 2026
- Logos Global Management LP 2.67M sh · $52.08M · Q2 2026
- Weiss Asset Management LP 2.58M sh · $50.27M · Q2 2026
- MPM BioImpact LLC 1.61M sh · $31.29M · Q2 2026
- Vivo Capital, LLC 1.40M sh · $27.26M · Q2 2026
- GREAT POINT PARTNERS LLC 855.81K sh · $16.66M · Q2 2026
- Trails Edge Capital Partners, LP 750.00K sh · $14.60M · Q2 2026
FAQ
How long has BVF INC/IL held MLTX?
BVF INC/IL has disclosed MLTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BVF INC/IL's current position in MLTX?
As of Q2 2026, BVF INC/IL holds 16.00M shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $311.54M, representing 7.97% of its reported portfolio and ranking #4.
Has BVF INC/IL been buying or selling MLTX?
In the latest 13F filing (Q2 2026), BVF INC/IL held unchanged its position in MLTX. The position peaked in Q4 2023 at 21.75M shares.
Which other funds hold MLTX?
Other major institutional holders of MLTX include Deep Track Capital, LP, Cormorant Asset Management, LP, Logos Global Management LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.